Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of SY-2101 (Oral Arsenic Trioxide) in APL
NCT04996030Phase 1Suspended
- Sponsor
- Syros Pharmaceuticals
- Start
- Sep 2021
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Arsenol in acute promyelocytic leukemia (APL) (4 arms), sponsored by Syros Pharmaceuticals. Primary endpoints: Maximum Observed Plasma Concentration of SY-2101 at Day 26 and Area Under the Curve of SY-2101 at Day 26. Started Sep 2021; status: suspended.
02
Drugs
Arsenol
03
Conditions
acute promyelocytic leukemia (APL)
Beyond the preview
Go deeper on NCT04996030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04996030.